Observational studyNeurology2026
Amyloid PET Burden, CSF Biomarkers, and
Observational study in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04204642 (SEarchiNg biomarkErs Cerebral Amyloid Angiopathy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA): Italian Network for the Study of CAA
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesIatrogenic cerebral amyloid angiopathy (iCAA) is a rare form of CAA believed to result from β-amyloid (Aβ) transmission during neurosurgical procedures. We aimed to compare amyloid PET burden, CSF biomarkers, and
methodsIn this single-center, cross-sectional study, adults fulfilling diagnostic criteria for probable sCAA or iCAA who underwent amyloid PET and CSF assessment between 2021 and 2024 were included. Amyloid burden was quantified using Centiloid scaling of
resultsNinety-five patients were included (24 with iCAA, 71 with sCAA; median age 56.5 vs 70 years). Patients with iCAA showed significantly higher amyloid deposition (median Centiloid 57.3 vs 30.5; DISCUSSION: Patients with iCAA exhibit higher amyloid burden and a distinct biomarker profile compared with those with sCAA, supporting a divergent-possibly exogenous-mechanism of amyloid propagation. TRIAL REGISTRATION INFORMATION: SENECA, ClinicalTrials.gov Identifier: NCT04204642 (submitted on December 19, 2019).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.